Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 8, 2026European Cardiology ReviewOpen Access

The CARDIOLIPID Plan: A Cardiovascular Risk-centred Implementation Framework for the Diagnosis and Management of Dyslipidaemia: Experts’ Proposal

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Guideline implementation for dyslipidaemia remains suboptimal in clinical practice, characterized by persistent therapeutic inertia and fragmented decision-making despite effective therapies and established guidelines.

Design

Expert proposal and conceptual implementation framework

Key result

The CARDIOLIPID Plan is a proposed expert framework integrating cardiovascular risk assessment and personalised lipid-lowering intervention to improve guideline implementation for dyslipidaemia.

Authors

SSStanisław SurmaMBMarcin BarylskiRSRoland E. Schmieder

Discussion

Loading...

Member takes

Overview

Addresses therapeutic inertia in dyslipidaemia management; extends ESC/EAS guidelines via a risk-centred implementation framework.

Key Points

  • The aim is to enhance the practical application of guidelines for dyslipidaemia management and reduce therapeutic inertia.
  • Development of the CARDIOLIPID Plan integrating cardiovascular risk assessment and lipid intervention.
  • Incorporation of expert interpretations of existing guidelines and evidence.
  • Emphasis on a structured, sequential pathway to improve clinical decision-making and treatment intensification.
  • The CARDIOLIPID Plan aims to provide clarity and usability in clinical practice.
  • It supports early treatment intensification, potentially reducing cardiovascular risk.
  • Validation in real-world settings is necessary to assess its effectiveness in improving treatment outcomes.

Structured PICO

I
Intervention
The CARDIOLIPID Plan (a cardiovascular risk-centred implementation framework)

The CARDIOLIPID Plan provides a structured, practical framework to help clinicians overcome therapeutic inertia and better implement existing lipid-lowering guidelines.

Limitations

  • Requires validation in real-world settings to assess its impact on treatment outcomes and cardiovascular risk reduction
  • Requires validation in real-world settings to assess impact on treatment outcomes and cardiovascular risk reduction

Cite This Study

Surma et al. (2026) studied Dyslipidaemia. CARDIOLIPID Plan was evaluated. The CARDIOLIPID Plan is a proposed expert framework integrating cardiovascular risk assessment and personalised lipid-lowering intervention to improve guideline implementation for dyslipidaemia.

synapsesocial.com/papers/6a70e2f4ac440176ef2990a5https://doi.org/10.15420/ecr.2026.08
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The 2026 ACC/AHA Dyslipidemia Guideline: A Critical and Transatlantic Perspective on Personalized Lipid Management2026
  2. 2Contemporary diagnostics, classification, and treatment of dyslipidemias according to international guidelines 2025-20262026
  3. 3Global Lipid Guidelines: More Aligned Than They Appear2026 · 1 citations
  4. 4A practical guide to the management of dyslipidaemia2026 · 6 citations
  5. 5A 360° Perspective on Cardiovascular Prevention: the International Lipid Expert Panel SiMple tIps for the heaLthy hEart (ILEP-SMILE)2025 · 12 citations